Active PI3K abrogates central tolerance in high-avidity autoreactive B cells

Area of Science:

• Immunology
• Molecular Biology
• Autoimmunity

Background:

• Central tolerance mechanisms normally eliminate high-avidity autoreactive B cells in the bone marrow.
• Breaches in these mechanisms contribute to B cell-mediated autoimmune diseases.
• Understanding tolerance breakdown pathways is crucial for developing autoimmune therapies.

Purpose of the Study:

• To investigate the role of PI3K-P110α activation in the tolerance of high-avidity autoreactive B cells.
• To determine how PI3K pathway activation affects B cell development and tolerance.

Main Methods:

• Utilized a mouse model with constitutively active PI3K-P110α expressed in B cells.
• Analyzed B cell tolerance, bone marrow egress, peripheral differentiation, and activation.
• Assessed antibody secretion in vitro and autoantibody production in vivo.

Main Results:

• B cell-intrinsic PI3K-P110α activation abrogated central B cell tolerance in mice.
• Activated B cells escaped the bone marrow and differentiated in peripheral tissues.
• These B cells could secrete antibodies in vitro but not autoantibodies in vivo.

Conclusions:

• PI3K pathway activation enables high-avidity autoreactive B cells to bypass central tolerance.
• Late stages of peripheral tolerance remain intact, preventing in vivo autoantibody production.
• Targeting the PI3K pathway may offer therapeutic strategies for autoimmune diseases.